« Return to News | Awards & Advancement

MMG names Chris Middleton vice president of technology

Friday, February 10, 2012 11:47 AM

MMG, a global clinical trials patient recruitment group, part of Ketchum, has appointed Chris Middleton vice president of technology.

Middleton will oversee all new technology products and application, service and infrastructure development. He will provide leadership and strategic direction for MMG's portfolio of technology-based patient recruitment efforts.

Middleton is a software industry veteran with a track record in complex software development across the healthcare, privacy, biometrics and enterprise integration industries, both in the U.S. and internationally. In addition to being a software architect and technology manager for companies such as CGI-AMS, Software AG, Deutsche Post DHL and Daon, Middleton has held leadership positions for software startups and founded Scaled Objects in 2007.

"Chris' passion for developing novel technology solutions that bridge gaps between patients and the services they need is perfectly suited for achieving MMG's aggressive goals for innovating and meeting our clients' needs,” said John Benbrook, CEO of MMG.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.